Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DeCODE Genetics Moves Heart Attack Prevention Candidate Into Phase IIb

This article was originally published in The Pink Sheet Daily

Executive Summary

Positive Phase IIa results have encouraged the biopharma to move forward with additional testing of the leukotriene A4 hydrolase inhibitor.

You may also be interested in...



Trouble In Iceland: DeCODE Scrambles To Escape Cash Crisis

Personalized medicine firm digs its way out of suffocating debt, hoping mystery investors will help the company survive 2009.

Trouble In Iceland: DeCODE Scrambles To Escape Cash Crisis

Personalized medicine firm digs its way out of suffocating debt, hoping mystery investors will help the company survive 2009.

DeCODE Suspends Phase III Heart Attack Prevention Trial

Manufacturing problem that caused dissolution decline in veliflapon tablets could take several months to resolve.

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel